Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-JMF-04
- Development stage
- Preclinical
- Lead developer
- University Hospital Ulm
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
177Lu-JMF-04 is a preclinical-stage radiopharmaceutical being developed for the imaging and treatment of CXCR4-expressing malignancies. It is a DOTA-conjugated peptide analog of EPI-X4, an endogenous peptide antagonist of C-X-C motif chemokine receptor 4 (CXCR4) derived from human serum albumin. Labeled with the beta-emitting radionuclide lutetium-177 (177Lu), 177Lu-JMF-04 is designed as a theranostic agent to target CXCR4-overexpressing cancer cells, delivering localized radiation to destroy tumor tissue. Preclinical studies have demonstrated that 177Lu-JMF-04 possesses high affinity for CXCR4, favorable hydrophilicity, and an improved biodistribution profile compared to 177Lu-Pentixather, characterized by low background activity and low liver uptake, though with accumulation in the kidneys.
- Other names
- [177Lu]Lu-JMF-04
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on 177Lu-JMF-04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-JMF-04.